ISIS 721744-CS3: An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517249-15-00

Acronym

ISIS721744-CS3

Enrollment

Registered

2024-11-04

Start date

2020-10-22

Completion date

2024-12-19

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Angioedema

Brief summary

1. Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity

Detailed description

1. The time-normalized HAE attacks (monthly) by treatment, 2. Plasma PKK levels, plasma proenzyme activation and cHK levels, 3. Consumption of on-demand medications, 4. Angioedema Quality of Life (AE-QoL) questionnaire score

Interventions

DRUGISIS 721744

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
1. Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity	—

Secondary

Measure	Time frame
1. The time-normalized HAE attacks (monthly) by treatment, 2. Plasma PKK levels, plasma proenzyme activation and cHK levels, 3. Consumption of on-demand medications, 4. Angioedema Quality of Life (AE-QoL) questionnaire score	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026